Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Summary

The purpose of this study is to evaluate how effective Olaparib is when given as a treatment for primary or recurrent, unresectable or metastatic melanoma. This research study involves targeted therapy. -The name of the study drug involved in this study is: Olaparib (also known as Lynparza)

Timeline

Start

2022-10-04

Primary completion

2026-05-01

Completion

2027-05-01

Outcome

Outcome not reported

Stopped: “Principal Investigator left the institute”

Drugs

Indications